JAZZ Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.16B

+6.17%

6.413

-2.83%

984.62M

+9.67%

4.338

+158.23%

1.10B

+5.41%

5.433

-165.86%

Estimates Revision

The market is revising Upward the revenue expectations for Jazz Pharmaceuticals plc (JAZZ) for FY2025, with the revenue forecasts being adjusted by 0.29% over the past three months. During the same period, the stock price has changed by 16.63%.

Revenue Estimates for FY2025

Revise Upward

+0.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+52.92%

In Past 3 Month

Stock Price

Go Up

+16.63%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 206.60 USD with a low forecast of 147.00 USD and a high forecast of 247.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

147.00

Averages

206.60

High

247.00

Current: 0.000

Low

147.00

Averages

206.60

High

247.00

Morgan Stanley

Sean Laaman

Overweight

maintain

$205 -> $225

2026-01-08

New

Reason

Morgan Stanley

Sean Laaman

Price Target

$205 -> $225

2026-01-08

New

maintain

Overweight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on Jazz Pharmaceuticals to $225 from $205 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Piper Sandler

David Amsellem

Overweight

upgrade

$147 -> $219

2025-12-10

Reason

Piper Sandler

David Amsellem

Price Target

$147 -> $219

2025-12-10

upgrade

Overweight

Reason

Piper Sandler analyst David Amsellem raised the firm's price target on Jazz Pharmaceuticals to $219 from $147 and keeps an Overweight rating on the shares. With Jazz recently announcing positive top-line results from the pivotal HERIZON-GEA-01 study evaluating novel bispecific HER2-directed antibody zanidatamab in HER2+ first-line advanced/metastatic gastroesophageal adenocarcinoma, the firm is updating its model to reflect significantly less risk-adjustment associated with its sales estimates for the product.

UBS

Ashwani Verma

Buy

Neutral

downgrade

$163 -> $188

2025-11-24

Reason

UBS

Ashwani Verma

Price Target

$163 -> $188

2025-11-24

downgrade

Buy

Neutral

Reason

UBS analyst Ashwani Verma downgraded Jazz Pharmaceuticals to Neutral from Buy with a price target of $188, up from $163. Following the strong Phase 3 GEA update and a 25% stock move, Jazz now appears fairly valued with a balanced risk/reward profile, the analyst tells investors in a research note. The positive study meaningfully improves the outlook, but with recent oncology momentum already reflected in the valuation and no major catalysts ahead, UBS sees limited upside/downside.

Baird

Brian Skorney

maintain

$160 -> $209

2025-11-18

Reason

Baird

Brian Skorney

Price Target

$160 -> $209

2025-11-18

maintain

Reason

Baird analyst Brian Skorney raised the firm's price target on Jazz Pharmaceuticals to $209 from $160 and keeps an Outperform rating on the shares. The firm said its HERIZON-GEA001 top line appears to be a best-case scenario.

Truist

Buy

maintain

$205 -> $220

2025-11-18

Reason

Truist

Price Target

$205 -> $220

2025-11-18

maintain

Buy

Reason

Truist raised the firm's price target on Jazz Pharmaceuticals to $220 from $205 and keeps a Buy rating on the shares following "positive" HERIZON-GEA-01 topline data. Current indications alone could drive Ziihera peaks sales greater than $2B, according to the firm. However, given breadth of HER2+ cancers for which Herceptin/Enhertu are standard of care, Truist thinks there's plenty of upside from Ziihera, which the firm views as pipeline-in-a drug.

BofA

Buy

maintain

$230 -> $247

2025-11-18

Reason

BofA

Price Target

$230 -> $247

2025-11-18

maintain

Buy

Reason

BofA raised the firm's price target on Jazz Pharmaceuticals to $247 from $230 and keeps a Buy rating on the shares. Favorable Phase 3 topline data from the HERIZON-GEA-01 study in gastric cancer suggest Ziihera is an approvable drug in first-line GEA, a market the firm estimates could equate to greater than $600M in the U.S. and greater than $1.1B in global peak sales, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Jazz Pharmaceuticals PLC (JAZZ.O) is 7.81, compared to its 5-year average forward P/E of 7.97. For a more detailed relative valuation and DCF analysis to assess Jazz Pharmaceuticals PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

7.97

Current PE

7.81

Overvalued PE

10.32

Undervalued PE

5.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

7.57

Current EV/EBITDA

7.82

Overvalued EV/EBITDA

8.92

Undervalued EV/EBITDA

6.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.20

Current PS

2.39

Overvalued PS

2.66

Undervalued PS

1.74

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

JAZZ News & Events

Events Timeline

No data

News

5.0

01-08PRnewswire

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development

5.0

01-08Newsfilter

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development

9.0

01-07Benzinga

Jazz Pharmaceuticals Reports Ziihera Trial Shows Significant Survival Benefits

People Also Watch

Frequently Asked Questions

What is Jazz Pharmaceuticals PLC (JAZZ) stock price today?

The current price of JAZZ is 161.13 USD — it has increased 0.55 % in the last trading day.

What is Jazz Pharmaceuticals PLC (JAZZ)'s business?

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

What is the price predicton of JAZZ Stock?

What is Jazz Pharmaceuticals PLC (JAZZ)'s revenue for the last quarter?

Jazz Pharmaceuticals PLC revenue for the last quarter amounts to 1.13B USD, increased 6.74 % YoY.

What is Jazz Pharmaceuticals PLC (JAZZ)'s earnings per share (EPS) for the last quarter?

Jazz Pharmaceuticals PLC. EPS for the last quarter amounts to 4.08 USD, increased 19.30 % YoY.

What changes have occurred in the market's expectations for Jazz Pharmaceuticals PLC (JAZZ)'s fundamentals?

How many employees does Jazz Pharmaceuticals PLC (JAZZ). have?

Jazz Pharmaceuticals PLC (JAZZ) has 2800 emplpoyees as of January 10 2026.

What is Jazz Pharmaceuticals PLC (JAZZ) market cap?

Today JAZZ has the market capitalization of 9.79B USD.